- Home
- KYMR vs LNTH Comparison
KYMR vs LNTH Comparison
Compare KYMR & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- LNTH
- Stock Information
- Founded
- KYMR 2015
- LNTH 1956
- Country
- KYMR United States
- LNTH United States
- Employees
- KYMR N/A
- LNTH N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KYMR Health Care
- LNTH Health Care
- Exchange
- KYMR Nasdaq
- LNTH Nasdaq
- Market Cap
- KYMR 4.3B
- LNTH 3.8B
- IPO Year
- KYMR 2020
- LNTH 2015
- Fundamental
- Price
- KYMR $63.94
- LNTH $55.20
- Analyst Decision
- KYMR Strong Buy
- LNTH Buy
- Analyst Count
- KYMR 19
- LNTH 6
- Target Price
- KYMR $68.95
- LNTH $74.17
- AVG Volume (30 Days)
- KYMR 665.0K
- LNTH 1.3M
- Earning Date
- KYMR 11-04-2025
- LNTH 11-06-2025
- Dividend Yield
- KYMR N/A
- LNTH N/A
- EPS Growth
- KYMR N/A
- LNTH N/A
- EPS
- KYMR N/A
- LNTH 2.39
- Revenue
- KYMR $43,735,000.00
- LNTH $1,525,933,000.00
- Revenue This Year
- KYMR $60.88
- LNTH N/A
- Revenue Next Year
- KYMR N/A
- LNTH $1.98
- P/E Ratio
- KYMR N/A
- LNTH $22.78
- Revenue Growth
- KYMR N/A
- LNTH 1.95
- 52 Week Low
- KYMR $19.45
- LNTH $47.25
- 52 Week High
- KYMR $65.69
- LNTH $111.29
- Technical
- Relative Strength Index (RSI)
- KYMR 63.12
- LNTH 49.67
- Support Level
- KYMR $56.75
- LNTH $50.16
- Resistance Level
- KYMR $61.21
- LNTH $61.92
- Average True Range (ATR)
- KYMR 3.12
- LNTH 2.65
- MACD
- KYMR -0.01
- LNTH -0.43
- Stochastic Oscillator
- KYMR 83.30
- LNTH 40.59
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.